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Obtaining immediate results makes testing for albuminuria at
the point of care far superior to central laboratory assays.
Here we determined if a quantitative desk-top system could
identify and monitor patients with microalbuminuria. Urinary
albumin excretion was measured in 259 patients of a
population cohort study where they collected 24-h urines
and first morning void samples prior to three clinic visits at
three week intervals. The albumin concentration was
determined with both an in-office HemoCue Albumin 201
system and a central laboratory BNII nephelometer. The
median (interquartile-range) urinary albumin concentration
in the first morning void, intra-individual variability in
patients excreting more than 30 mg/day and the prediction
of microalbuminuria in subsequent 24-h collections
measured by each technique were statistically
indistinguishable. The HemoCue system met the FDA
criterion for precision while being at its border for accuracy.
Our study shows that determination of urinary albumin
concentration in a first morning void by the HemoCue
point-of-care system provides a good alternative to central
laboratory analysis identifying and monitoring patients with
microalbuminuria.
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Microalbuminuria has been established as a valuable risk
marker for renal and cardiovascular complications.1–5 Present
guidelines recommend periodical measurement of urinary
albumin excretion especially in patients with diabetes and/or
hypertension.6,7 Generally, urinary albumin is measured in a
central laboratory facility. Transfer of sample, measurement
in daily laboratory routine, and result reporting includes a
time delay. As with other risk markers, such as blood
pressure, one would like to have the immediate results
available during consultation for two reasons. First, such test
results facilitate the physician to make a risk assessment
during consultation that can help decide whether to start
preventive interventions. Second, based on direct showing of
the test results, the physician is able to motivate patients to
change lifestyle, start therapy, or increase therapy compliance.
Direct risk assessment, as well as the option of giving direct
feedback to the patient, is considered to result in better
treatment compliance and efficacy.8–10
Several ‘desktop’ point-of-care systems are presently
marketed, which are able to detect urinary albumin at the
patient–doctor visit. Urine dipsticks strips are available to
determine total protein or albumin level. However, these
dipsticks provide only semi-quantitative results. Recently,
quantitative ‘desktop’ systems have become available (DCA
Vantage; Siemens, and HemoCue Albumin 201; HemoCue,
A¨ngelholm, Sweden). These devices could indeed offer the
possibility of moving the measurement of albuminuria to the
doctors’ office and the patients’ side. However, before we can
bring such strategy into clinical practice, it is necessary to
determine whether these devices are as accurate and precise
as the currently used central laboratory measurements. Intra-
assay and inter-assay coefficient of variation for measurement
of urinary albumin with the HemoCue point-of-care system
have been reported to be slightly higher compared with
measurement of urinary albumin with a central laboratory
nephelometer.11 However, no study has investigated whether
such devices can be used in clinical practice to identify
subjects with abnormal levels of urine albumin and to
monitor patients over time.
This study evaluates the value of the HemoCue Albumin
point-of-care system in comparison with measurement of
urinary albumin by nephelometry in a central laboratory
(Dade Behring BNII, Marburg, Germany). First, we tested
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whether the point-of-care system measures as accurately and
precisely as the central laboratory nephelometer. Second, it
was evaluated whether the point-of-care system detects
subjects with microalbuminuria as good as a central
laboratory nephelometer. Third, we tested whether the
point-of-care system can monitor urinary albumin excretion
over time as good as a central laboratory nephelometer.
RESULTS
Study population
A total of 259 subjects were included in the study. The
characteristics of the study population are described in
Table 1. Since the Prevention of Renal and Vascular End-stage
disease study is enriched for patients with microalbuminuria,
the prevalence of participants with urinary albumin excretion
X30 mg/24-h was, in this study, slightly higher (10.4%)
than what is reported in the general population, being
approximately 7%.12
Analytical comparison between the point-of-care system
and laboratory nephelometer
Out of the 259 first morning void samples obtained at the
first visit, 151 samples measured with central laboratory
nephelometer gave results in the measuring range of the
point-of-care system and were used for analytical compar-
ison; 108 samples were below 5 mg/l. The median (inter-
quartile range) urinary albumin concentration in the first
morning void was 11 mg/l (8–17) as measured with the point-
of-care system and 9.5 mg/l (6.6–14.4) measured with
laboratory nephelometer (P¼ 0.082) (Figure 1). The Bland–
Altman plot shown in Figure 2 was used to investigate
possible systematic errors in the measurement of urinary
albumin concentration in a first morning void. Data are
presented on the log scale because of the large concentration
range that was studied. The mean(±s.d.) difference in
urinary albumin concentration between both the methods
was 1.8 mg/l (7.4).
The intra-assay coefficient of variation of 10 consecutive
measurements ranged between 4.9 and 8.0% in the urinary
albumin concentration range of 5 to 150 mg/l. The urinary
albumin concentration of 94% of all urine samples collected
at visit 1, measured with the point-of-care system, differed by
p10 mg/l or p30% compared with measurement with
central laboratory nephelometer.
Diagnostic performance of urinary albumin concentration
assessed by point-of-care and in a central laboratory
The area under the receiver operating characteristic (ROC)
curve for urinary albumin concentration in a first morning
void sample, for predicting urinary albumin excretion
X30 mg in subsequent 24-h urine collections (as measured
Table 1 | Baseline characteristics
Number 259
Male (%) 50.2
Caucasian (%) 96.1
Age (years) 58.6 (11.5)
Weight (kg) 79.4 (15.0)
Use of BP-lowering agents (%) 31.3
DBP (mm Hg) 73.6 (8.7)
SBP (mm Hg) 127.5 (18.5)
Use of lipid-lowering drugs (%) 21.6
Cholesterol (mmol/l) 4.9 (1.0)
Use of anti-diabetica (%) 2.7
Glucose (mmol/l) 5.2 (0.8)
Serum creatinine (mmol/l) 78.0 (17.2)
First morning void UAC (mg/l) 6.0 (2.4–45.2)
ACR (mg/g) 5.6 (2.5–70.5)
24-h urine UAC (mg/l) 6.2 (2.4–83.0)
ACR (mg/g) 8.2(3.4–105.1)
UAE (mg/24 h) 10.9 (4.4–166.2)
Low normal (UAE 0–15 mg/24 h) 68.3%
High normal (UAE 15–30 mg/24 h) 21.2%
Microalbuminuria (UAE X30 mg/24 h) 10.4%
BP, blood pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure.
Data are given as means with standard deviation, with the exception of 24-h urine
albumin excretion (UAE) and urinary albumin concentration (UAC) and albumin:-
creatinine ratio (ACR), which are given as medians with 95% confidence interval.
UAE, UAC, and ACR are measured in a central laboratory.
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Figure 1 | Box–whisker plot for urinary albumin concentration
in a first morning void measured with central laboratory
nephelometer and point-of-care system. Interquartile range
and fifth and ninety-fifth percentile are shown.
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Figure 2 | Bland–Altman plot for central laboratory
nephelometer and point-of-care system. The solid line
represents the mean difference between the point-of-care system
and laboratory nephelometer. The dashed line represents the
mean difference±1.96 s.d. limits.
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in the central laboratory), was 0.82 (0.73–0.91) and 0.90
(0.82–0.97), as measured with the point-of-care system and in
the central laboratory, respectively (Figure 3, P¼ 0.209). The
sensitivity and specificity at various cut-off values, among
them cut-off values that are used in clinical practice and
discriminator values, are shown in Table 2. The sensitivity at
20 mg/l, being the clinically used cut-off value, was similar
between the point-of-care system and central laboratory
nephelometer measurement, whereas the difference in speci-
ficity was small, although statistically significant (P¼ 0.041).
Monitoring urinary albumin excretion over time
The median intra-individual coefficients of variation of
urinary albumin concentration (95% confidence interval) are
presented in Table 3. The difference in the intra-individual
coefficient of variation of urinary albumin concentration
measured with the point-of-care system versus that measured
with central laboratory nephelometer is related to baseline
urinary albumin excretion. In subjects with albuminuria
below 15 mg/24-h, central laboratory measurement per-
formed significantly better. In subjects with albuminuria
between 15 and 30 mg/24-h, mean intra-individual coeffi-
cient of variation was not significantly different (P¼ 0.105),
whereas in subjects with albuminuriaX30 mg/24-h the mean
values were similar (P¼ 0.459).
Using albumin:creatinine ratio instead of urinary albumin
concentration
The area under the curve for the albumin:creatinine ratio
in a first morning void to predict microalbuminuria in
subsequent 24-h urine samples is 0.93 (0.87–0.99) for all
participants (Figure 3), 0.91 (0.83–0.99) for men, and 0.94
(0.85–1.02) for women. Although numerical differences are
observed among the area under the ROC curves for urinary
albumin concentration, measured with point-of-care system
and central laboratory nephelometer, and albumin:creatinine
ratio, these differences did not reach statistical significance,
neither for all subjects nor in gender specific sub-group
analyses. In the overall population, the sensitivity of the
albumin:creatinine ratio at 30 mg/g, the clinically used cut-
off value for microalbuminuria, was significantly lower
compared with the sensitivity of the urinary albumin
concentration at 20 mg/l measured with the point-of-care
system or central laboratory nephelometer (Table 2,
Po0.001). In contrast, specificity at 30 mg/g was significantly
higher compared with urinary albumin concentration
measured with the point-of-care system and central labora-
tory nephelometer (Table 2, Po0.001). Gender-specific cut-
off values have been proposed by Warram et al.13(17 mg/g
for males and 25 mg/g for females). The sensitivity at the
gender-specific cut-off values was not significantly different
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Figure 3 | ROC-curve analysis of the urinary albumin
concentration determined by point-of-care system and
central laboratory nephelometer and albumin:creatinine ratio
determined by nephelometry in predicting urinary albumin
excretion X30 mg/24-h in subsequent 24-h urine collections.
Area under the curve (95% confidence interval) for UAC point-of-
care system, UAC central laboratory, and ACR central laboratory
were 0.82 (0.73–0.91), 0.90 (0.82–0.97), and 0.93 (0.87–0.99),
respectively (P¼NS). Abbreviations: UAC, urinary albumin
concentration; ACR, albumin:creatinine ratio.
Table 2 | Sensitivity and specificity of the urinary albumin
concentration in a first morning void in predicting urinary
albumin excretion X30 mg/24-h in subsequent 24-h urine
collections
UAC cut-off (mg/l) Sensitivity (%) Specificity (%)
Point-of-care system
7.5 90.0 (86.3–93.7) 41.0 (35.0–47.0)
10.0 80.0 (75.1–84.9) 61.8 (55.9–67.7)
12.5 73.3 (67.9–78.7) 76.9 (71.8–82.0)
15.0 70.0 (64.4–75.6) 83.5 (79.0–89.0)
16.5=DV 70.0 (64.4–75.6) 87.1 (83.0–91.2)
20.0 56.7 (50.7–62.7) 93.2 (89.3–95.7)
Central laboratory
7.5 87.9 (83.9–91.9) 65.9 (60.1–71.7)
10.0 86.7 (82.6–90.8) 80.7 (75.9–85.5)
10.5=DV 86.7 (82.6–90.8) 81.8 (77.1–86.5)
12.5 76.7 (71.6–81.8) 89.5 (85.8–93.2)
15.0 71.5 (66.0–76.0) 94.2 (91.4–97.0)
20.0 56.7 (50.7–62.7) 97.3 (95.3–99.3)a
ACR cut-off (mg/g) Sensitivity (%) Specificity (%)
Central laboratory
Overall
10.0 80.0 (75.1–84.9) 85.8 (81.5–90.0)
15.0=DV 73.3 (67.9–78.7) 95.9 (93.5–98.3)
20.0 66.7 (61.0–72.4) 98.2 (96.6–99.8)
30.0 36.7 (30.8–42.5)b 100.0a
Male
17 53.3 (47.2–59.4) 99.1 (97.9–100.0)a
Female
25 60.0 (54.0–66.0) 98.2 (96.6–99.8)
ACR, albumin-to-creatinine ratio; DV, discriminator value; UAC, urinary albumin
concentration.
aPo0.05 versus specificity urinary albumin concentration measured with point-of-
care at 20 mg/l.
bPo0.05 versus sensitivity urinary albumin concentration measured with point-of-
care system and central laboratory at 20 mg/l.
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compared with urinary albumin concentration determined
with the point-of-care system and central laboratory, whereas
specificity was significantly higher compared with urinary
albumin concentration determined with the point-of-care
system (Table 2, P¼ 0.008).
The median intra-individual coefficient of variation of
the albumin:creatinine ratio in all subgroups was significantly
lower compared with urinary albumin concentration
(Table 3). In subjects with albumin excretion X30 mg/24-h,
the difference was however numerically nearly similar.
Using 24-h urine collection instead of a first morning void
The median (interquartile range) urinary albumin excretion
in the 24-h urine was 17.5 mg/l (10.5–29.1] measured with
the point-of-care system and 14.6 mg/l (9.6–23.7) measured
with laboratory nephelometer (P¼ 0.103). The area under
the ROC curve of the urinary albumin excretion in a 24-h
urine collection in predicting urinary albumin excretion
X30 mg in subsequent 24-h urine collections (as measured in
the central laboratory) was 0.86 (0.77–0.94) and 0.92
(0.86–0.99), measured with the point-of-care system and in
the central laboratory, respectively (P¼ 0.190). The area
under the ROC curve of the albumin:creatinine ratio was 0.90
(0.83–0.97) (P¼ 0.465 versus 24-h urinary albumin excretion
measured with the point-of-care system).
DISCUSSION
This study evaluated whether for urinary albumin measure-
ment a novel point-of-care system can replace a central
laboratory nephelometer, which is the present gold standard.
We demonstrated precision of the point-of-care system below
8.0% and accuracy of 94%. Furthermore, the area under the
ROC- curve to screen for patients with microalbuminuria did
not differ significantly among the urinary albumin concen-
tration, measured with the point-of-care system or central
laboratory nephelometer, and albumin:creatinine ratio mea-
sured in a central laboratory. Lastly, the intra-individual
coefficient of variation of urinary albumin concentration
measured with the point-of-care system was significantly
higher compared with that measure with the central
laboratory nephelometer, but not in subjects with micro-
albuminuria. However, the intra-individual coefficient of
variation of the albumin:creatinine ratio was significantly
lower in all subgroups compared with urinary albumin
concentration measured with the point-of-care system or
central laboratory nephelometer.
The first aim of our study was to determine the precision
and accuracy of the point-of-care system. The Food and Drug
Administration (FDA) provided criteria for precision and
accuracy for a new laboratory method (point-of-care system)
to replace the reference method (central laboratory nephel-
ometer).14,15 We evaluated if the point-of-care system
complied with the FDA criteria. FDA criterion for precision
is a coefficient of variation p10% based on 10 consecutive
measurements. Our data indicate that FDA criterion for
precision was achieved. To meet FDA criterion for accuracy,
95% of samples with urinary albumin concentration
determined by point-of-care system should be within 30%
or 10 mg/l of the urinary albumin concentration determined
by central laboratory nephelometer. Since 94% of the urine
samples measured with point-of-care were within 30% or
10 mg/l limits, the accuracy of the point-of-care system was at
the border of FDA criterion. The observations that the
HemoCue point-of-care system correlates well with measure-
ment in a central laboratory, is in line with previous reports.
For instance, a study on elderly male patients with diabetes
comparing the performance of the HemoCue system with a
nephelometer laboratory analyzer showed that the albumin
concentration correlated well between the two methods.16
Another study also showed high correlation for measurement
of urinary albumin concentration with point-of-care system
and central laboratory nephelometer, although intra-assay
and interassay coefficient of variations were somewhat higher
with the point-of-care system.11 Yet, it has not been
investigated whether this point-of-care system can be used
in clinical practice to identify subjects with abnormal levels of
urinary albumin and to monitor urinary albumin excretion
over time.
The second aim of the study was to investigate if the
point-of-care system can be reliably used to screen for
patients with urinary albumin excretion X30 mg/24-h in
subsequent 24-h urine collections. The relatively high area
under the ROC curve indicates that the urinary albumin
concentration measured with the point-of-care system is an
accurate screening test. Although the area under the curve for
the laboratory nephelometer is numerically higher than
that of the point-of care system, the difference did not
reach statistical significance. Moreover, the sensitivity and
Table 3 | Intra-individual coefficient of variation of the urinary albumin concentration and albumin:creatinine ratio
Urinary albumin concentration Albumin:creatinine ratio
Laboratory nephelometer coefficient
of variation (%)
Point-of-care system coefficient
of variation (%)
Laboratory nephelometer coefficient
of variation (%)
All values 29.6 (4.2–89.7) 41.7 (5.7–90.6)a 18.8 (3.0–69.5)b
Sub-groups
0–15 mg/24 h 28.8 (4.3–80.5) 40.7 (5.5–99.3)a 16.0 (2.1–88.7)b
15–30 mg/24 h 31.8 (7.0–127.6) 48.5 (14.1–135.1) 20.9 (3.6–102.1)b
X30 mg/24 h 23.8 (1.7–100.5) 24.1 (3.2–80.3) 20.0 (3.8–44.2)b
aPo0.05 coefficient of variation point-of-care system versus central laboratory.
bPo0.05 coefficient of variation albumin:creatinine ratio value versus urinary albumin concentration measured with point-of-care system.
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specificity at the traditionally used cut-off values of urinary
albumin concentration to screen for microalbuminuria were
nearly similar between the two methods. Finally, the
diagnostic performance of the 24-h urinary albumin excre-
tion measured with the point-of-care system did not differ
significantly from that of the 24-h urinary albumin excretion
and albumin:creatinine ratio measured with the laboratory
nephelometer.
Of note, our results with respect to the diagnostic
performance of the urinary albumin concentration measured
in a first morning void sample to predict an albumin
excretion X30 mg in subsequent 24 h urine collections are
consistent with other studies that applied a nephelometer in a
central laboratory. Several reports have shown that the area
under the ROC curve for urinary albumin concentration in a
first morning void sample (or spot morning urine collection)
to predict microalbuminuria are high, ranging between 0.88
and 0.93.17,18
A potential disadvantage of the HemoCue point-of-care
system is the fact that the system does not measure creatinine
concentration. Expressing albuminuria in urine samples of an
individual subject as the albumin over creatinine ratio instead
of urinary albumin concentration has been suggested to result
in more consistent results due to the fact that it ‘corrects’ for
variation in hydration status in a particular subject.19 However,
our results show that for the entire study population the
area under the ROC curve, sensitivity, and specificity at the
clinically used cut-off values for urinary albumin concentra-
tion and the albumin:creatinine ratio to screen for micro-
albuminuria in subsequent 24 h urine collections are nearly
similar. Notably, the sensitivity of the albumin:creatinine ratio
at 30 mg/g, the clinically used cut-off value for microalbumi-
nuria, was remarkably lower compared with the sensitivity at
20 mg/l the urinary albumin concentration cut-off value for
microalbuminuria. Therefore, we believe that for screening
purposes measuring urinary creatinine to determine the
albumin:creatinine value adds no significant value.
The final aim of this study was to determine whether the
point-of-care system could be used to monitor urinary
albumin excretion over time. Our results demonstrate that
for subjects with low levels of albuminuria, the point-of-care
system showed significant difference in comparison with the
nephelometer in a central laboratory. However, from a
clinical point of view, one would only be interested to
monitor urinary albumin levels in subjects with abnormal
values. For microalbuminuric subjects, the performance of
the point-of-care system is numerically comparable. In
addition, we compared the variability of the albumin:crea-
tinine ratio, determined in a central laboratory, with
measurement of only the urine albumin concentration by
the point-of-care system. Although intra-individual varia-
bility of the albumin:creatinine ratio is significantly lower
than urinary albumin concentration in all subgroups of
patients, the variability was numerically nearly similar in
microalbuminuric subjects. We, therefore, conclude that the
point-of-care system provides a good alternative to monitor
microalbuminuric subjects over time if measurement of
albumin:creatinine ratio is not possible or not feasible from
an economic perspective.
This study used first morning void samples to evaluate if a
point-of-care system can be used to screen for microalbu-
minuria and to monitor microalbuminuria over time. One
might argue that spot urine collections would have been
more appropriate, since these can be collected during
consultation and might therefore be more practical. The
rationale to use first morning void samples is based on
various guidelines advocating the use of first morning void
collections over spot morning collections for initial testing of
microalbuminuria.6,20 According to these guidelines, the
albumin concentration in first morning void samples
correlates better with 24-h albuminuria, which is the gold
standard. It should, however, be mentioned that albumin
concentration is not yet universally accepted as a screening
method for albuminuria.
Material costs do not prevent use of a point-of-care system
versus a central laboratory. Material costs for immunochem-
ical measurement of urinary albumin in a central laboratory
vary around $1.5 US. Material costs for (semi-)quantitative
point of care systems (Hemocue 201, Clinitek test, Micral II
test) vary between $1.5 and $2.5 US, except for DCA Vantage
analyzer, which is approximately four times more expensive.
This study has a few limitations and some issues need to
be addressed. This study included a relatively small number
of subjects. Other studies investigating diagnostic perfor-
mance of the urinary albumin concentration or albumin:-
creatinine ratio in a first morning void or spot urine sample
to detect microalbuminuria in subsequent 24-h urine
samples included more subjects. Nevertheless, the results in
our study are nearly similar to the values in these reports,
which found areas under the ROC curves of 0.87 and
0.92.17,18 The number of subjects with urinary albumin
excretion 430 mg/24-h is also relatively small (n¼ 25).
Therefore, the suggestion that the urinary albumin concen-
tration derived from a first morning void in microalbumi-
nuric subjects to monitor urinary albumin excretion over
time should be read with caution and confirmatory studies
are warranted. Finally, one should keep in mind that these
results are obtained in a predominantly non-diabetic
Caucasian cohort. Further research in specifically diabetic
population should corroborate our findings.
In conclusion, the point-of-care system measures urinary
albumin concentration with sufficient precision and accuracy
compared with a central laboratory measurement. Determi-
nation of urinary albumin concentration in a first morning
void sample using the HemoCue point-of-care system
provides a good alternative to a central laboratory analyzer
to identify subjects with microalbuminuria. In case micro-
albuminuria is diagnosed, this point-of-care system can also
be used to monitor urinary albumin excretion over time.
These properties of the point-of-care system enhance its use
in the doctor’s office and provide possibility for immediate
feedback to the patient.
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MATERIALS AND METHODS
Study population
This study was conducted on subjects who participated in the
Prevention of Renal and Vascular End-stage disease study. This
study is a prospective cohort study in The Netherlands that
investigates the relation between urinary albumin excretion and
renal and cardiovascular disease. The participating subjects visit an
outpatient department once every 3 years for measurement of health
status. Details of the study protocol have been published else-
where,21 and can be found on www.PREVEND.org. The Prevention
of Renal and Vascular End-stage disease study has been approved by
the local medical ethics committee and is performed in accordance
with the guidelines of the Declaration of Helsinki Principles.
Study design
Participants in this study were informed verbally and in writing
about the study during their regular visit to the outpatient
department. In case subjects agreed to participate, three appoint-
ments were made to visit the research unit with a time interval of
3 weeks between visits. Before the first visit, written and verbal
instructions for collection of urine samples were given. Subjects were
asked to collect a 24-h urine sample from 2200 to 2200 h. The next
morning, after finishing the 24-h urine collection, the subjects were
asked to collect a mid-stream first morning void sample. Subjects
were advised to store their urine in plastic containers at 4 1C until
they visited the research unit that same day. At each of the three
visits, participants thus delivered a 24-h urine collection and a first
morning void sample.
Analytical methods
For this study, urinary albumin and creatinine concentrations were
determined for fresh urine samples within 48 h after collection.
Urinary albumin concentration was measured with the HemoCue
Albumin 201 point-of-care system (HemoCue) and with a Behring
BNII analyzer (Dade Behring) in a central laboratory with standard
laboratory methods. The intra-assay and inter-assay coefficient of
variation for urinary albumin measured by BNII analyzer evaluated
in our laboratory were 2.2 and 2.6%, respectively. The lower limit of
detection was 2.40 mg/l. The HemoCue Albumin 201 point-of-care
system is equipped with a lower respectively upper limit of detection
of 5 and 150 mg/l. Urinary creatinine was determined by an
enzymatic method (Modular Analytics SWA; Roche, Tokyo, Japan)
with intra-assay and inter-assay coefficient of variation evaluated in
our laboratory of 1.9 and 2.1%, respectively. To calculate 24-h
urinary albumin excretion, total volume of the 24-h collection was
determined and multiplied by albumin concentration.
Statistical methods
Urine samples collected at the first visit with central laboratory
nephelometer measured urinary albumin concentration values in the
measurement range of the point-of-care system were used for
analytical comparison. A Bland–Altman plot was used to investigate
the agreement of the urinary albumin concentration measured in a
first morning void with the point-of-care system and central
laboratory nephelometer.22 The intra-assay coefficient of variation
of ten consecutive measurements was calculated to determine
precision of the point-of-care system. The percentage of samples
collected at visit one with urinary albumin concentration measured
by point-of care system within 30% or 10 mg/l of the urinary albumin
concentration determined by central laboratory nephelometer was
calculated to determine accuracy of the point-of-care system.
All first morning void samples obtained at the first visit were
used to determine the predictive value of the urinary albumin
concentration, measured by the point-of-care system and central
laboratory nephelometer, as a screening test to identify urinary
albumin excretion X30 mg in 24-h urine collections (microalbu-
minuria) obtained at the second and third visit. Because of natural
variation in urinary albumin excretion the average of the 24-h
urinary albumin excretion obtained at the second and third visit was
used to classify subjects in the normoalbuminuric or microalbumi-
nuric range. ROC curves were used to determine the discriminative
power of the urinary albumin concentration measured with the
point-of-care system and central laboratory nephelometer. Sensitiv-
ity and specificity for various cut-off values were calculated to
determine the diagnostic properties of the urinary albumin
concentration, measured with point-of-care system and central
laboratory nephelometer, to predict microalbuminuria. The value
lying nearest to the intersection of the curve with the 100%
sensitivity to 100% specificity diagonal was chosen as discriminator
value. Calculation of the 95% confidence intervals of the sensitivity
and specificity was performed according the guidelines described by
Altman.23 McNemar test was used to test differences in sensitivity
and specificity between the point-of-care system and laboratory
nephelometer.
To determine whether the point-of-care system can replace a
central laboratory to monitor urinary albumin excretion over time,
the intra-individual coefficient of variation of the urinary
albumin concentration in the three first morning voided collections
was calculated. Intra-individual coefficient of variation was
calculated as the ratio of the standard deviation of the three first
morning voids and the average urinary albumin concentration
in the three first morning voids. Coefficients of variations were
not calculated if participants did not submit three urine collections,
or in case urinary albumin concentration was below the detection
limit.
A central laboratory offers the advantage that urinary creatinine
can be determined as well. It has been suggested that in an
individual the albumin:creatinine ratio shows less variability than
albumin concentration alone, since it more or less corrects for
hydration status. We therefore investigated whether correction for
urinary creatinine concentration improved the diagnostic perfor-
mance of the urinary albumin concentration in predicting a 24-h
urine albumin excretion X30 mg in 24-h urine collections. For this
purpose, both urinary albumin and urinary creatinine measurement
were performed in the central laboratory. Since creatinine excretion
varies with gender, we also performed sub-group analyses in men
and women. Furthermore, the intra-individual coefficient of
variation in albumin:creatinine ratio was determined in the first
morning urine samples and compared to the corresponding value
for albumin concentration.
In an additional analysis, the performance of the point-of-care
system was tested by comparing urinary albumin levels and
diagnostic performance of urinary albumin excretion and albu-
min:creatinine ratio in a 24-h urine, collected at the first visit and
measured with the point-of care system and central laboratory
nephelometer.
Data are presented as means±95% confidence interval (95% CI)
to describe areas of the ROC-curves, and as means±standard error
for other variables. In case of non-normal distribution data are
presented as medians with interquartile range. Differences between
intra-individual coefficient of variations were tested for significance
according the Wilcoxon signed rank test. A P-value p0.05
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(two-sided) was considered to indicate a statistically significant
difference. All analyses were performed using SPSS version 14.
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